Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs > Compugen (CGEN)

6:01AM Compugen announces results showing its CGEN-15001T drug

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
surf1944 Member Profile
 
Followed By 446
Posts 21,866
Boards Moderated 2
Alias Born 09/11/06
160x600 placeholder
Compugen Ltd. Reports Third Quarter 2014 Financial Results "Business Wire" - 10/29/2014 7:13:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 10/29/2014 7:07:45 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 10/28/2014 7:02:43 AM
Compugen Discloses Successful Validation Results for Novel B7/CD28–like Cancer Immunotherapy Target Candidate "Business Wire" - 10/27/2014 7:01:00 AM
Compugen Third Quarter 2014 Conference Call Scheduled for Wednesday, October 29, 2014 at 10:00 AM ET "Business Wire" - 10/22/2014 7:11:00 AM
Compugen Achieves Second Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer "Business Wire" - 10/14/2014 2:02:00 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 10/14/2014 1:49:35 PM
Compugen Immune Checkpoint Results Being Presented at Three Scientific Conferences "Business Wire" - 10/6/2014 7:08:00 AM
Compugen Discloses New Results for Novel Target Candidate for Cancer Immunotherapy "Business Wire" - 10/1/2014 7:01:00 AM
Compugen Announces Presentations of Results for CGEN-15001 Supporting Immune Tolerance Induction "Business Wire" - 9/29/2014 7:04:00 AM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 9/5/2014 6:00:20 AM
Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) "Edgar (US Regulatory)" - 9/4/2014 4:46:16 PM
Securities Registration (foreign Private Issuer) (f-3) "Edgar (US Regulatory)" - 8/26/2014 4:06:25 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 8/26/2014 4:02:33 PM
Compugen Appoints Mr. Ari Krashin as Chief Financial Officer "Business Wire" - 8/25/2014 7:09:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 8/25/2014 7:01:31 AM
Compugen Reacquires Baize’s Financial Interest in Pipeline Product Candidates "Business Wire" - 8/21/2014 7:09:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 8/21/2014 7:01:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 8/11/2014 7:00:02 AM
Compugen Ltd. Reports 2nd Quarter 2014 Financial Results "Business Wire" - 8/6/2014 7:11:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 8/6/2014 7:00:28 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 7/31/2014 4:15:40 PM
Compugen Second Quarter 2014 Conference Call Scheduled for Wednesday, August 6, 2014 a... "Business Wire" - 7/31/2014 7:37:00 AM
Compugen Second Quarter 2014 Conference Call Scheduled for Tuesday, August 5, 2014 at 10:00 AM EDT "Business Wire" - 7/29/2014 7:00:00 AM
Compugen to Present Immune Checkpoint Related Research at Two Scientific Conferences "Business Wire" - 7/24/2014 7:00:00 AM
surf1944   Thursday, 02/02/12 10:57:15 AM
Re: surf1944 post# 109
Post # of 144 
6:01AM Compugen announces results showing its CGEN-15001T drug may have potential for cancer immunotherapy (CGEN) 5.30 : Co announced results demonstrating the therapeutic potential of CGEN-15001T as a drug target for treatment of multiple cancers by means of monoclonal antibody ("mAb") therapy. These results indicate that CGEN-15001T is expressed on numerous types of cancer, such as carcinomas, sarcomas, melanoma and hematological cancers as well as on immune cells. These findings, together with previous results supporting its active immunomodulatory effect, 'strongly support CGEN-15001T's potential as a powerful drug target for treatment of various solid and hematological cancers, an area of great interest to the pharmaceutical industry.'


surf's up......crikey



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist